Docetaxel-induced Scleroderma in A Breast Cancer Patient: A Case Report.

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Paclitaxel and docetaxel are taxane antineoplastic agents used to treat various cancers.
• These drugs function by inhibiting microtubule depolymerization, crucial for cell division.
• Common side effects include cardiotoxicity, neutropenia, and mucositis.

Observation:

• Scleroderma is an uncommon but serious side effect associated with taxane chemotherapy.
• It typically manifests as edematous changes in extremities, progressing to skin sclerosis.
• This case highlights scleroderma development in a patient undergoing docetaxel for breast cancer.

Findings:

• Docetaxel-induced scleroderma can lead to significant cutaneous and subcutaneous tissue changes.
• Early recognition and drug discontinuation are key to managing this adverse event.
• Steroid therapy and rehabilitation may be necessary for severe cases.

Implications:

• This case underscores the importance of monitoring for rare dermatological side effects of taxanes.
• Awareness among oncologists and dermatologists is crucial for prompt diagnosis and intervention.
• Further research into the mechanisms and optimal management of taxane-induced scleroderma is warranted.